Jisandai (Bingtongsha) latest selling price and buying guide in 2024

Epclusa (Epclusa), as an oral antiviral drug developed by Gilead Sciences, is designed to treat chronic hepatitis C (HCV) of all genotypes. Its core components include sofosbuvir (Sofosbuvir) and velpatasvir (Velpatasvir), the former as a nucleotideNS5B polymer Enzyme inhibitors can effectively inhibit the replication of hepatitis C virusRNA, and the latter, as an NS5A inhibitor, can prevent the replication of virus RNA and the assembly of virus particles. The combined effect of these two ingredients enables Jisandai (Bingtonsa)to be able to widely cover HCV different genotypes, improve the success rate of treatment and reduce the risk of drug resistance.

At present, Jisandai (Bingtonsha) has been launched in China and has been successfully included in the medical insurance directory, providing patients with a domestic purchase channel. Its price is relatively affordable, about more than 3,000 yuan. However, specific prices and medical insurance reimbursement policies may vary by region, and patients are advised to consult their local hospital or pharmacy for accurate information. Compared with domestic prices, generic drugs in India and Bangladesh are cheaper, costing only a few hundred yuan, and their drug ingredients are basically the same as the domestic versions.

Jisandai (Bingtonsha) is suitable for patients with HCV infection of all genotypes, especially those with mild to moderate cirrhosis. For patients with severe cirrhosis (decompensated cirrhosis), the combined use of Bintonsa and ribavirin can further improve the therapeutic effect. The recommended dosage is one tablet once daily, and the continuous treatment period is 12 weeks. However, before starting treatment, patients should consult their doctor to determine the most appropriate treatment option.

Clinical trial results show that Jisandai (Bingtonsha) has significant therapeutic effect, and its cure rate (SVR12) can reach 95% or more. Although common adverse reactions such as headache, fatigue, nausea, etc. are usually mild to moderate, for patients with severe liver damage, their liver function indicators should be closely monitored during medication.